Mark Lackner
CIK: 0001777413
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (66.7%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (33.3%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ZNTL
Zentalis Pharmaceuticals, Inc.
Officer
Discretionary Trading P&L
Holdings
About Lackner Mark
Lackner Mark (SEC CIK 0001777413) files insider reports with the SEC as Chief Scientific Officer of Zentalis Pharmaceuticals, Inc. (ZNTL).
Signal8 holds 2 ownership filings by Lackner Mark, all Form 4s, filed between Jan 3, 2025 and Feb 5, 2025. Those filings report 3 transactions, from Jan 2, 2025 to Feb 3, 2025. Signal8's Form 4 history starts in Sep 2024.
The business address on Lackner Mark's filings is in SAN DIEGO, CA.
Recent filings by Lackner Mark
Other insiders filing for Zentalis Pharmaceuticals, Inc. (ZNTL)
- Bruns Ingmar, Chief Medical Officer
- WALTERS GROUP, 10% Owner
- Johnson David Michael, Director
- Skvarka Jan, Director
- Walker Luke Nathaniel, Director
- Kariuki Enoch, Director